Currently Viewing:
American Psychiatric Association 2019 Annual Meeting
Dr David Kingdon on the Principles Underlying the Use of CBT in Psychosis
May 19, 2019
Dr Jonathan Avery on the Dangers of Misdiagnosing or Mistreating Concurrent Psychiatric and Substance Use Disorders
May 19, 2019
Studies Reveal Loneliness, Trauma Effects Among Minority Urban Women
May 20, 2019
Hochschild Gives Psychiatrists a View of Bridging the Political Chasm
May 20, 2019
Dr Lori Raney Outlines the Advantages and Limitations of Treating Mental Health Disorders in Primary Care Settings
May 20, 2019
Dr Steven Adelsheim Discusses Changing Stigmas Around Mental Illness in Young People
May 20, 2019
Dr Jacob Ballon: Coordinated Teams, Collaboration Are Key to Supporting People With Psychosis
May 21, 2019
TRANSFORM-2 Results on Esketamine Published, Along With Caveats
May 21, 2019
Poll Finds Most Workers Can Get Mental Health Care, but a Third Worry About Seeking It
May 21, 2019
Adam Simmons on Patient Preferences When Taking Antipsychotic Medications
May 21, 2019
Alkermes' Novel Schizophrenia Drug Shows Less Weight Gain, Addressing Top Patient Complaint
May 21, 2019
Where Culture and Science Collide: How Ethnic, Social Factors Affect Response to Psychotropic Drugs
May 22, 2019
Dr Godfrey Pearlson on the Merits of Using Biological Measures to Classify Psychiatric Diseases
May 23, 2019
Dr Isaac Galatzer-Levy Explains How a Predictive Algorithm Uses Machine Learning to Predict PTSD Risk
May 23, 2019
Dr King Davis Explains the Privacy Dangers of Digitizing Archives, Including Psychiatric Records
May 24, 2019
Dr David Kingdon Discusses How CBT Techniques Tailored to Psychosis Can Help Patients Feel Understood
May 30, 2019
Dr Jonathan Avery Discusses Causes and Consequences of Concurrent Mental Illness and Substance Use Disorders
May 31, 2019
Adam Simmons Outlines Efficacy of ALKS 3831 Across Subgroups of Patients With Schizophrenia
June 11, 2019
Dr Lori Raney Defines Integrated, Collaborative Care for Behavioral Health
June 13, 2019
Dr David Kingdon Describes How CBT Can Fit Into a Psychosis Treatment Plan
June 17, 2019
Dr Steven Adelsheim Discusses the Importance of Early Diagnosis for Young People With Psychosis
June 20, 2019
Dr Isaac Galatzer-Levy Explains the Importance of Accurately Predicting PTSD After a Traumatic Event
June 22, 2019
Dr Jonathan Avery Explains How Substance Use Affects the Care of Patients With Mental Illness
June 23, 2019
Dr David Kingdon on the Factors Predicting CBT Success in Psychosis
June 25, 2019
Currently Reading
Adam Simmons Explains the Importance of Finding New Treatment Options for Schizophrenia
June 29, 2019

Adam Simmons Explains the Importance of Finding New Treatment Options for Schizophrenia

Adam Simmons, director of clinical program management, Alkermes, explained why researchers are seeking new treatments for schizophrenia, such as the investigational treatment ALKS 3831, despite the efficacy of a commonly used antipsychotic, olanzapine. Simmons was interviewed at the 175th Annual Meeting of the American Psychiatric Association in San Francisco, California.


Adam Simmons, director of clinical program management, Alkermes, explained why researchers are seeking new treatments for schizophrenia, such as the investigational treatment ALKS 3831, despite the efficacy of a commonly used antipsychotic, olanzapine.

Transcript

Can you discuss the importance of finding new treatment options for people with schizophrenia?

Although there’s been a number of treatments and new therapies that have been developed since olanzapine’s come to the market, we still know that olanzapine is still one of the most effective antipsychotics, that it’s one of the most commonly used. And that being despite the fact that olanzapine has this propensity for causing large, clinically significant amounts of weight gain.

So the objective here, and what it is that we’ve tried to do with our development program, is demonstrate that we still have that same efficacy of olanzapine that has been established and is very well supported in the literature, but reducing some of that weight gain. And the benefits there, of course, are that we know that weight gain is associated with, as you mentioned, cardiovascular disease, diabetes, as well as the social reasons and stigma that goes along with increased amounts of weight gain.

So for people that need the efficacy of olanzapine but without that additional weight gain and all the disadvantages that go along with that, that’s where we think that 3831 offers a benefit for patients.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up